Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Clark, PE; Downs, TM; Efstathiou, JA; Flaig, TW; Friedlander, T; Guru, KA ...
Published in: J Natl Compr Canc Netw
October 2017
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
October 2017
Volume
15
Issue
10
Start / End Page
1240 / 1267
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Treatment Outcome
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Neoplasm Invasiveness
- Humans
- Combined Modality Therapy
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., … Gurski, L. A. (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(10), 1240–1267. https://doi.org/10.6004/jnccn.2017.0156
Spiess, Philippe E., Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, et al. “Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 10 (October 2017): 1240–67. https://doi.org/10.6004/jnccn.2017.0156.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240–67.
Spiess, Philippe E., et al. “Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 15, no. 10, Oct. 2017, pp. 1240–67. Pubmed, doi:10.6004/jnccn.2017.0156.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240–1267.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
October 2017
Volume
15
Issue
10
Start / End Page
1240 / 1267
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Treatment Outcome
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Neoplasm Invasiveness
- Humans
- Combined Modality Therapy
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis